How Customized Copay Analytics Help Brands Build Market Share
Data needs vary from brand to brand. It’s critical for pharma brands to employ customized copay analytics strategies for their patient access programs.
3 Ways Pharmacy Benefit Programs Can Prepare for Biosimilar Drugs
By understanding your contract, communicating with your PBM, and working with a partner to craft your pharmacy strategy, you’ll be well prepared for the rise of biosimilar drugs.
5 Strategies for Achieving Transparency in Your Pharmacy Contract
How can you build more transparency in your pharmacy contract? We lay out five critical strategies to ensure you have control and oversight over your program.
Webinar - Pharmacy Benefits 101: What Employers Need to Know About PBMs and Drug Spend
In this Truveris webinar, we join Mployer Advisor to tackle pharmacy benefits 101. What should payers know about PBMs as they plan for 2023?
3 Patient Access Strategies Setting Innovative Brands Apart
The gross-to-net bubble is inflating. What patient access strategies are leading brands using to combat this trend?
7 Indicators that Your Drug is a Strong Candidate for Accumulator and Maximizer Programs
How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.
Webinar - Transparency in Pharmacy: Innovative Strategies to Drive Outcomes for Self-Funded Plans
How can you inject more transparency into your pharmacy plan? Watch the recording of our webinar.
The Truveris Pharmacy Benefits Glossary of Terms
Truveris’ Pharmacy Benefits Glossary of Terms provides important definitions and context to help navigate the pharmacy benefits landscape.
3 Patient Access Strategies for New Biosimilar Brands
As biosimilars gain more popularity in the market, pharma manufacturers must think differently about launch strategies to gain market share.
What are Biosimilars and Why Do They Matter?
If you work in the pharmacy ecosystem, you’ve probably heard buzz around “biosimilars.” What should you know about this innovative type of medication?
6 Takeaways from the Asembia 2022 Specialty Pharmacy Summit
6,000 pharmacy professionals attended Asembia this year. What were the key takeaways from the conference?
Webinar - HR Leaders' Perspective: Priorities and Challenges for Employee Benefits in 2022 and Beyond
Watch Truveris’ exclusive Human Resources round table, originally recorded on June 8th, 2022.
What Self-Funded Plans Should Know About Copay Assistance Programs
Plan sponsors are looking for new ways to contain specialty costs. How should they evaluate new copay assistance strategies?
How to Manage High-Cost Specialty Drug Spend for Self-Funded Plans
As pharmacy costs increase, what are strategies plan sponsors can take to control specialty pharmacy spend?
Webinar - Copay Maximizers and Alternative Funding: What Self-Funded Plans Should Know
How are copay maximizers and alternative funding impacting plans – and members? Watch our on-demand webinar to learn more.
Truveris Launches the First Member-Centric Patient Engagement Solution, oneRx™
Truveris announces the launch of oneRx, the only drug price transparency solution that helps members navigate their pharmacy benefits.
4 Reasons Why Member Engagement Fuels a Pharmacy Benefits Plan
After you procure a strong PBM contract, make sure your members are engaging with the plan productively.
The Three Pillars of Pharmacy Benefits Strategy
By framing your pharmacy benefits strategy around these three pillars, you’ll construct a more cost-effective, accessible pharmacy program.
Four Dynamic Areas of a Pharmacy Benefits Contract You Should Know
While a pharmacy benefits contract is a powerful lever for managing spend, it is also very complicated, with variables impacted by market and industry dynamics.
3 Strategies for Pharma Brands to Navigate the January Claims Drop
Many brands experience a drop in claims during January. What strategies successfully drive adherence during the beginning of the year?
How Member-Centricity Drives Effective Pharmacy Strategy
What is member-centricity? Why should plan sponsors and brokers strive to reimagine their pharmacy program with members in mind?
Asembia 2021: Four Key Takeaways
Four core themes from Asembia 2021 that will drive dialogue in the specialty pharmacy ecosystem in 2022 – and beyond.
The 340B Program: How Manufacturers, Plan Sponsors, and Brokers Should React
340B is increasingly a part of the pharmacy conversation. How should stakeholders react to the program?
Gene Therapy and Cell Therapy: Key Payer Considerations
Many gene therapy products are soon to be released to the market. What do payers need to know about these highly-expensive specialty drugs?
Industry Update: The Impact of State Legislation on Copay Accumulator Programs
Several states have passed legislation that prohibits the use of copay accumulator adjustment programs. How does this affect your organization?
Webinar - Payer Strategies for Anticipating and Managing Gene Therapy
Watch Truveris’ on-demand webinar outlining how Payers can best anticipate and manage new gene therapies.
What's the Difference between a Specialty Drug and a Non-Specialty Drug?
Looking forward to the future of pharmacy, it’s critical to understand how a specialty drug is defined, how it differs from traditional, non-specialty drugs, and how specialty is impacting employers’ benefit plan designs.